Glycemic homeostasis of ultrasound-assisted Murraya koenigii (Linn.) Spreng. bark extract in streptozocin-induced diabetes in rats

Abstract

AbstractNumerous diseases have been linked to oxidative stress, emphasizing its role in pathogenicity. This study employed an ultrasound-assisted extraction process to obtain extracts from the bark of Murraya koenigii (L) Spreng. A thorough analysis was conducted on these dry extracts to determine their total phenolic and flavonoid content across four solvent fractions: n-hexane, ethyl acetate, n-butanol, and aqueous. Among the solvent fractions, ethyl acetate and n-butanol showed higher levels of total flavonoid content (TFC) and total phenolic content (TPC) compared to the others. The ethyl acetate fraction displayed the highest TPC (58.27 ± 4.20 mg GAE/g) and TFC (878.67 ± 40.38 mg QE/g) at 250 µg/mL concentration. Furthermore, the in-vitro antioxidant capacity of the ethyl acetate fraction was assessed for its ability to scavenge DPPH and hydrogen peroxide, revealing a concentration-dependent effect with IC50 values of 154.6 ± 6.2 and 55.12 ± 4.28 μg/mL, respectively. In a controlled experiment using streptozocin-induced diabetic rats, administering UMBE-EA at doses of 100 and 200 mg/kg notably improved blood glucose levels and body weight. Furthermore, several biochemical indicators, such as total protein levels, serum insulin, and the activities of enzymes like SGOT, SGPT, and ALP, as well as liver glycogen, showed significant enhancements. The antioxidant enzyme activities, including SOD, CAT, and GSH, returned to more favorable levels, and TABAR levels were normalized. In conclusion, the findings from this study strongly suggest that UMBE-EA possesses substantial anti-diabetic efficacy in Wistar rats, primarily attributed to its remarkable antioxidant properties and capacity to scavenge free radicals. These results provide valuable insights into the potential therapeutic benefits of UMBE-EA in diabetes management.